FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition

NCT05937295 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Fibrolamellar Hepatocellular Carcinoma

Interventions

DRUG: Fusion-VAC-XS15

Sponsor

University Hospital Tuebingen